Moody’s Says Pfizer’s US Clearance of COVID-19 Vaccine Has Positive Credit

(Reuters) – The rating agency Moody’s Investors Service said on Sunday that the authorization of the COVID-19 vaccine from Pfizer Inc. in the United States is positive from a credit point of view.

“The approval is positive from a credit standpoint due to the incremental earnings and cash flow from the vaccine sales,” said Moody’s bit.ly/2Lx7CeW. “The revenue and profit opportunities for Pfizer are significant because it has put the price of the vaccine at a profit.”

The Pfizer / BioNTech vaccine in a large clinical trial was 95% effective in preventing disease. US regulators late on Friday authorized the vaccine’s emergency use, following similar moves from the UK and Canada.